Skip to main content

About us

Making life saving drugs affordable and available for more patients

This is our story

As a relatively young company we keep a straight line
from our values to our vision to our focus. The sum of the three, points to our direction. Helping more people.

The founding

CHRETO was funded in 2010, as a spin out of Novozymes, by the inventor Jan Kyhse-Andersen and Torben Jørgensen to develop and commercialize a novel protein purification technology for bio-manufacturing.

Our values

CHRETO is based on a set of fundamental values.
Creativity, Honesty, Respect and Trustworthiness

The technology

In 2014 the company acquired the rights to the original IP related to protein purification technology from Novozymes.


Our office in Hørsholm

The CHRETO headquarters are based in Hørsholm Denmark. Here in the out-skirts of Copenhagen we generate our ideas and development. We plan for further enhancement of our products and our communication.

Laboratory in Hørsholm

There are many synergies in our decision to place our laboratory cohesive to our offices. Research and development slides effortlessly from theory to physical achievements. Enhancing our "One team - one dream" focus.

International community

Our commercialisation, collaboration and communication reaches far beyond the physical borders, and into the global community of the pharmaceutical industry. We travel responsibly, thus utilising the world as our base for the modernisation and optimisation of the development of gama globulins (IgG) from human plasma.

Meet The Team

We are an exceptional, multidisciplinary team based in Copenhagen Denmark. Our passion for bringing our concept and product to market is heartfelt. That is our fuel.

CEO, Founder

Jan Kyhse-Andersen

Jan Kyhse Andersen is the CEO and founder of CHRETO ApS, and more importantly, the inventor of the CHRETO® Technology. He holds a PhD in Chemical Engineering from the Technology University of Denmark and has more than 30 years’ experience as inventor, entrepreneur and manager in the biotechnology and diagnostic industry.

He is the inventor of Semi Dry Electroblotting, a technique that significantly improved Western Blotting as well as the first to commercialize the apparatus. He was founder of JKA BIOTECH and co-founder of Kem-En-Tec A/S.

Chairman of the board

Kim Bjørnstrup

Kim Bjørnstrup, Chairman of the board at CHRETO ApS

Kim has a management career of more than 30 years in the pharmaceutical industry. He graduated from Copenhagen University in 1984 and was licensed as a Lawyer in 1987. From 1987 to 1992, he was Internal Legal Counsel to Lundbeck AS and Later Coloplast AS. From 1992 to 2010 Kim worked at Octapharma AG in Switzerland, as Vice Chairman /CEO. In 2010, he re-started Xeltis AG a Swiss biotech specialized in self-generating heart valves. He was also the CEO of BPL UK a company from 2013 to 2014.

Member of the board

Lars Bäckman

Lars Bäckman holds the position as VP of Corporate Development with Biotage AB since January 2007 and he is also the General Manager of Biotage subsidiary MIP Technologies.

Prior joining Biotage, Lars Bäckman held the position as SVP of Corporate Development at Affibody.

He has previous experiences acting as a lawyer at the Swedish law firm Hamilton & Co, specialized in Corporate Finance and Mergers & Acquisitions, and from Venture Management at the Business Development firm Googol. Mr. Bäckman holds a LLM from the Stockholm University and was born in 1961.

Member of the board

Susanne Wetterlin

Susanne holds a MSc in Toxicology from Karolinska Institutet 1992. Susanne has a management career of  more than 20 years in the chemical industry. From 1993 to 2014 she worked at Akzo Nobel and  between 2004 and 2014 she was European Sales Director in the area of adhesives and coatings. Susanne has a long experience related to environment and sustainability and had a position as CEO of Bastaonline AB from 2014 and 2022, focusing on building- and construction products.

Olof Nord

Olof Nord serves as Executive Vice President Business Development at Biotage. Dr. Nord is a Global Business Leader Executive with +25 years’ experience from various leading commercial roles in the Life Sciences, Healthcare, Diagnostics and Medtech industries, working at multinational companies like Abbott and Becton Dickinson. He is also one of the co-founders of the Swedish biopharma company Affibody. Olof holds a M.Sc. in Chemical Engineering and a Ph.D. degree in Biotechnology, both achieved from the Royal Institute of Technology (KTH) in Stockholm.

Frank Nygaard

Frank Nygaard serves as CMC Director, Drug Substance Development at Symphogen and has extensive hands-on experience with more than 20 years in biotech covering early and late phase R&D and technology transfers. He has been responsible for lead candidate selection, process development and technology transfers to CMOs for GMP manufacturing of drug substance and drug product as well as biochemical analysis and characterisation of protein therapeutics including monoclonal antibodies. He hold a M.Sc. in biochemistry and a Ph.D. degree in protein chemistry from the University of Copenhagen